Fresenius Medical Care AG & Co. KGaA
Financials
Valuation Metrics
Fresenius Medical Care AG & Co. KGaA's Market Cap is $12.15B. At end of 2025 it was $14.17B. Ranked #801 of 3,115 in US market (top 26%), #553 of 1,643 on NYSE (top 34%), #53 of 203 in Health Care Equipment & Services (top 26%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $12.15B | US#801/3,115 Sec#53/203 |
| Revenue | $21.95B | US#294/3,115 Sec#19/203 |
| Net Income | $1.06B | US#521/3,115 Sec#27/203 |
| Total Assets | $36.76B | US#402/3,115 Sec#20/203 |
| Net Assets | $14.75B | US#297/3,115 Sec#18/203 |
| Employees | 108,165 | US#99/3,115 Sec#6/203 |
| Value | ||
| P/E | 11.47x | US#481/3,115 Sec#7/203 |
| P/B | 0.82x | US#274/3,115 Sec#13/203 |
| PEG | 0.27x | US#396/3,115 Sec#13/203 |
| P/S | 0.55x | US#386/3,115 Sec#30/203 |
| EV/EBITDA | 6.15x | US#291/3,115 Sec#7/203 |
| FCF Yield | 16.46% | US#250/3,115 Sec#9/203 |
| Profitability | ||
| ROE | 7.18% | US#1,659/3,115 Sec#80/203 |
| ROA | 2.88% | US#1,430/3,115 Sec#91/203 |
| Op. Margin | 9.74% | US#1,594/3,115 Sec#83/203 |
| Revenue Growth | -0.47% | US#2,233/3,115 Sec#167/203 |
| Earnings Growth | 42.86% | US#546/3,115 Sec#30/203 |
| Financial Health | ||
| Debt Ratio | 141.45% | US#1,427/3,115 Sec#131/203 |
| Total Debt | $12.88B | US#343/3,115 Sec#16/203 |
| FCF | $2.00B | US#356/3,115 Sec#24/203 |
| Cash | $1.25B | US#585/3,115 Sec#31/203 |
| Current Ratio | 1.07x | US#2,173/3,115 Sec#185/203 |
| Net Debt/EBITDA | 3.01x | US#1,606/3,115 Sec#98/203 |
| Dividend | ||
| Div. Yield | 0.02% | US#1,721/3,115 Sec#56/203 |
| Div. Growth | 16.23% | US#313/3,115 Sec#10/203 |
| Performance | ||
| 1Y Return | -15.70% | US#2,217/3,115 Sec#150/203 |
| 1M Return | 1.69% | US#1,526/3,115 Sec#137/203 |
| From 52W High | -14.36% | US#1,256/3,115 Sec#103/203 |
| 1Y MDD | -19.49% | US#986/3,115 Sec#33/203 |
| Trading | ||
| Volume | 1,251,391 shares | US#1,918/3,115 Sec#131/203 |
| Trading Value | $28M | US#2,118/3,115 Sec#145/203 |
| Per Share | ||
| EPS | $1.97 | US#1,336/3,115 Sec#68/203 |
| BPS | $27.46 | US#963/3,115 Sec#58/203 |
Company Info
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.